obesity drug news today glp-1 october 23 2025 New oral delivers up to 12% weight loss in 36 weeks glp-1 obesity drug news today

Description

Efficacy of semaglutide versus liraglutide in clinical practice

doi: 10.1016/j.jcjd.2019.09.003 110 HusainMBirkenfeldALDonsmarkMDunganKEliaschewitzFGFrancoDRet al

Clinically Studied for Metabolic Health: CQR-300 has been evaluated in 6 human clinical trials and shown to support reductions in calorie intake, body weight, and body fatwhile improving markers like blood sugar, cholesterol, and blood pressure

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

Highlights The starting tirzepatide dosage for weight management is low (2.5 mg weekly) and is increased slowly (by 2.5 mg weekly after at least 4 weeks) because side effects are common but usually temporary and manageable